Market Access News | pharmaphorum

News

medicines and dollars - the price of prescription drugs

IRA negotiated prices revealed as Biden claims $6bn savings

The US government has published the finalised 'maximum fair prices' (MFPs) for the first 10 medicines subject to Medicare negotiations under the Inflation Reduction Act (IRA), shortly after

News

PBC drug choices rise in US with OK for Gilead's seladelpar

At the start of the year, there had been no new therapies for rare cholestatic liver disease primary biliary cholangitis (PBC) in the US for almost a decade.

News

Incyte builds GvHD presence with Niktimvo approval

The FDA has approved Incyte's axatilimab as a treatment for chronic graft-versus-host disease (GvHD), making it a companion to the company's Jakafi for the disorder.

News

woman suffering from uterine fibroid pain holding her abdomen

Theramex's uterine fibroid drug Yselty backed for NHS use

A daily oral therapy for uterine fibroids has been recommended for NHS by NICE, providing a new option for around 30,000 women in England and Wales.

News

Rachel Reeves appointed as Chancellor of the Exchequer by Keir Starmer, 5th July 2024

AstraZeneca said to be wavering on £450m UK vaccine plant

AstraZeneca's plan to invest £450 million ($578 million) in a vaccines manufacturing plant in the UK has been thrown into doubt, claims a report in the Financial Times.

News

AZ gets landmark approval for Imfinzi/Lynparza combo

AstraZeneca has become the first company to get approval for the combination of an immunotherapy with a PARP inhibitor for treating endometrial cancer.

IRA negotiated prices revealed as Biden claims $6bn savings

PBC drug choices rise in US with OK for Gilead's seladelpar

Incyte builds GvHD presence with Niktimvo approval

Theramex's uterine fibroid drug Yselty backed for NHS use

AstraZeneca said to be wavering on £450m UK vaccine plant

AZ gets landmark approval for Imfinzi/Lynparza combo

Amgen's Imdelltra scores again in small cell lung cancer

Discover a new era of healthcare panel engagement: Grounded ...

News

Editor's Picks